Document Detail


Combined intravenous treatment with ascorbic acid and desferrioxamine to reduce myocardial reperfusion injury in an experimental model resembling the clinical setting of primary PCI.
MedLine Citation:
PMID:  22653244     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: During reperfusion of ischemic myocardium, oxygen-derived free radicals are produced and can cause deleterious effects, known as reperfusion injury. We aimed to determine if a combination of the antioxidant ascorbic acid and an iron-chelating agent desferrioxamine, which reduces the production of the hydroxyl radical via ferrum-catalyzed reactions, can exert a protective action against reperfusion injury.
METHODS: Twenty-two young male farm pigs were anesthetized and subjected to 45 mins of ischemia and 3 and a half hours of reperfusion, in the left circumflex coronary artery territory, via the inflation and deflation of an angioplasty balloon. Animals were randomly assigned to receive either an intravenous infusion of 100 mg/ kg ascorbic acid and 60 mg/kg desferrioxamine (treatment group, TG) or an equal amount of normal saline (control group, CG). The I/R ratio, the ratio of the infarcted (necrotic) zone (I) to the myocardial area at risk (R) after 3 and a half hours of reperfusion, was calculated using the tetrazolium staining method. Left ventricular end diastolic pressure (LVEDP), number of episodes of ventricular arrhythmias, TIMI flow in the reperfused vessel, and left ventricular ejection fraction (LVEF) were evaluated within the first hour post reperfusion in order to assess further injury severity.
RESULTS: There was no significant difference in the I/R between the TG (27.9 ± 2.2%) and the CG (32.9 ± 2.4%) (p=0.15). In both groups there was a significant reduction in LVEF (-11.6 ± 2.28% for TG and -12.0 ± 2.27% for CG, p<0.01 for both groups) and a significant increase in LVEDP (+3.2 ± 0.9 mmHg for TG and +4.6 ± 0.9 mmHg for CG, p<0.01 for both groups) compared to the baseline values. No significant difference was noted between groups (p=0.61 for LVEF and p=0.60 for LVEDP values, at one hour post reperfusion). In all other parameters measured, no significant difference was observed between the study groups.
CONCLUSIONS: Intravenous treatment with a combination of the antioxidant ascorbic acid and the iron-chelating agent desferrioxamine does not provide significant protection against myocardial reperfusion injury.
Authors:
Georgios N Chatziathanasiou; Dimitrios N Nikas; Christos S Katsouras; Nikolaos D Kazakos; Vasiliki Bouba; Theodoros Vougiouklakis; Katerina K Naka; Lampros K Michalis
Related Documents :
1709234 - Electrophysiology and antiarrhythmic actions of e-4031 in the experimental animal model...
6496754 - Regional myocardial perfusion and wall thickening during ischemia in conscious dogs.
7139894 - Intermittent brief periods of ischemia have a cumulative effect and may cause myocardia...
22275044 - Bionic cardiology: exploration into a wealth of controllable body parts in the cardiova...
19388504 - Alpha2-adrenergic agonists and their role in the prevention of perioperative adverse ca...
10498144 - Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hellenic journal of cardiology : HJC = Hellēnikē kardiologikē epitheōrēsē     Volume:  53     ISSN:  2241-5955     ISO Abbreviation:  Hellenic J Cardiol     Publication Date:    2012 May-Jun
Date Detail:
Created Date:  2012-06-01     Completed Date:  2013-05-07     Revised Date:  2013-08-07    
Medline Journal Info:
Nlm Unique ID:  101257381     Medline TA:  Hellenic J Cardiol     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  195-204     Citation Subset:  IM    
Affiliation:
Michaelideion Cardiac Center, Ioannina Medical School, Ioannina, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antioxidants / therapeutic use*
Arrhythmias, Cardiac
Ascorbic Acid / therapeutic use*
Coronary Vessels / physiopathology*
Deferoxamine / therapeutic use*
Disease Models, Animal
Drug Therapy, Combination
Infusions, Intravenous
Male
Myocardial Infarction / drug therapy*,  pathology,  physiopathology
Myocardial Reperfusion Injury / physiopathology,  prevention & control*
Myocardium / pathology
Random Allocation
Stroke Volume
Sus scrofa
Chemical
Reg. No./Substance:
0/Antioxidants; 50-81-7/Ascorbic Acid; 70-51-9/Deferoxamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Homocysteine levels and MTHFR polymorphisms in young patients with acute myocardial infarction: a ca...
Next Document:  A propensity score-based comparison of flat panel digital detector fluoroscopy versus digital cinefl...